- Specialization
- Computer Vision
- Business
- Software Applications
- Market
- Healthcare
- Ecosystem
- Applications
- Customers
- Enterprises
More details
- Organization type
- Commercial Company
- Ecosystem
- Applications
- Business
- Software Applications
- Specialization
- Computer Vision
- Market
- Healthcare
- Customers
- Enterprises
- Delivery models
- Not classified
- Revenue models
- Not classified
- Listing status
- Not classified
- Latest equity round
- Not classified
- Reported funding amount
- Not classified
About
InVision Medical Technology builds clinically validated, FDA-cleared AI software for echocardiography, including automated LVEF measurement and cardiac-amyloidosis detection, selling primarily to health systems and clinical providers. Its differentiation is a decade of academic research, deep echocardiography datasets, regulatory clearances, and prospective randomized clinical evidence integrated into clinician workflows.
Market
InVision competes in clinical AI for cardiovascular imaging, particularly AI-assisted echocardiography interpretation, automated measurement, reporting, and cardiac-amyloidosis screening. Its positioning emphasizes clinically validated, FDA-cleared algorithms that work as post-processing software on standard DICOM studies and integrate with existing echo-lab workflows rather than requiring new scanners or hardware. Relative to focused competitors such as Us2.ai and Ultromics and broader imaging vendors such as Siemens and GE, InVision differentiates through a multi-product suite, prospective randomized evidence for LVEF, a large-scale EchoPrime vision-language model, and research-oriented cardiac-data applications.
Primary customers are hospitals and health systems—especially cardiology and echocardiography labs—that want AI-assisted interpretation, standardized measurements, and disease screening without purchasing new ultrasound hardware. Secondary customers include life-sciences and pharmaceutical organizations, plus medical-device companies, seeking structured cardiac imaging data, research-grade validation, or clinical AI partnerships.
At a Glance
Problem
InVision Medical Technology addresses the bottleneck and inconsistency of echocardiography interpretation. About 32 million heart ultrasounds are performed annually in the United States, and acquiring and interpreting each study requires more than an hour of physician and technician time. Human-to-human variation can also produce misdiagnosis and underdiagnosis, leaving clinically important disease undiscovered. The main use case is screening routine echocardiograms for cardiac amyloidosis, a rare but treatable condition that is frequently missed and can be surfaced without adding marginal clinician workload.
Product / Service
InVision provides clinically validated AI software for cardiovascular imaging. Its models analyze standard echocardiographic DICOM studies after acquisition, automate measurements such as left-ventricular ejection fraction, and identify suspected cardiac amyloidosis. The software is designed to fit existing workflows and integrate with PACS, Epic, and structured reporting systems, so hospitals do not need new scanners or specialized hardware. Precision LVEF and Precision Cardiac Amyloid have FDA 510(k) clearance; the company says blinded randomized-trial evidence demonstrated time savings and improved measurement consistency.
Market
The company competes in cardiovascular imaging AI, specifically AI-assisted echocardiography and software as a medical device for health systems and echo laboratories. The competitive set includes HeartFocus, Powerful Medical, and Volta Medical, while Viz.ai is an adjacent competitor offering FDA-cleared echocardiogram measurement and cardiac-amyloidosis detection. InVision differentiates through its decade-long academic research base, peer-reviewed clinical evidence, regulatory clearances, reimbursement support for its amyloidosis workflow through CPT Category III code 0932T, and deployment without new imaging hardware.
InVision appears to have moved beyond a pre-revenue research stage: its site describes live deployments through partners such as HeartLab, and identifies Y Combinator and Alexion, an AstraZeneca Rare Disease company, as backers or strategic partners. The company does not publicly disclose audited revenue in the cited materials, but Latka estimated approximately $2.1 million in annual revenue in 2025, which should be treated as a third-party estimate rather than a confirmed company figure.
Founders & Leadership
Funding History
Y Combinator
Recent News
Dandelion Health announced a partnership with InVision Medical Technology to integrate InVision’s echocardiography AI. The announcement accompanied Dandelion’s $14 million Series A financing.
Cardiovascular Business coverage identified InVision Medical Technology’s automated AI screening tool for adult echocardiography patients as a device intended to help physicians identify cardiac amyloidosis.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
InVision operates an enterprise healthcare-AI model, commercializing FDA-cleared cardiovascular-imaging software for health systems and providers through direct deployments and partnerships. Its products also benefit from a direct reimbursement pathway for certain AI-assisted echocardiography evaluations, while public sources do not disclose specific pricing or contract terms.